steven boyd, biotech stock review

Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

April 2019 Offering On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors...
AR THreats Report, Biotech Stock Reciew

AR Threats Report (CDC)

This report is dedicated to the 48,700 familieswho lose a loved one each year to antibiotic resistanceor Clostridioides difficile, and the...
candida auris, citius pharma, biotech stock review

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...

Latest article

Hagerty Garage and Social

Private Investor Meetup with Football Star Tim Wright.

Saturday August 6th, Delray Beach Exclusive cocktail hour with Super Bowl Champion and Dome Audio Founder Tim Wright.

What is NAC (N-Acetyl-L-Cysteine)? (Dr Eric Berg) What is NAC good for? (and How Much to Take?)

FDA Issues Final ‘Enforcement Discretion’ Guidance on NAC.

NAC Crosses Major Hurdle With FDA. Is Bucillamine Next. Josh Long | Aug 01, 2022 "Industry, and...